Published On: Tue, Dec 26th, 2017

Stocks With Noticeable Momentum: Callaway Golf (NYSE:ELY), Chipotle Mexican Grill (NYSE:CMG), Catabasis Pharmaceuticals (CATB)

Shares of Callaway Golf Company (NYSE:ELY) day-trade ended finally plunging -1.94% to close at $11.65. Callaway Golf (ELY) reported that CFO Robert Julian has resigned; names Brian Lynch as Interim CFO, effective recently; Julian’s departure not related to any discontract in accounting for financial reporting matters.

The firm announces that Robert Julian has left the company and that it has appointed Brian Lynch, its General Counsel, to the additional role of Interim CFO, effective recently. The firm emphasized that Mr. Julian’s departure was not related to any discontract in accounting or financial reporting matters and that there has been no adverse change in the business. The firm intends to consider both internal and external candidates in its search for a CFO.

ELY had a trade volume of 2.63 Million shares as compared to average trading capacity of 1066.84 shares. Shares price moved down from its 50 days moving average with 6.04% and remote positively from 200 days moving average with 4.23%. How NYSE:ELY Become Volatile Stock? Find Out Here

Chipotle Mexican Grill, Inc. (NYSE:CMG) stock in last trading session soared 0.63% to the closing price of $471.76. Chipotle (CMG) saw a key sales figure rise more than expected as it works to regain consumers’ trust after a series of food scares, but may have lost at least a little ground again in disclosing a possible data security issue.

The firm reported that it recently detected unauthorized activity on the network that supports its payment system in restaurants, but believes it has stopped the activity. It said its investigation is focused on restaurant transactions between March 24 and April 18 of this year, and would not provide further details since the investigation is still going on. A Chipotle representative said the company has notified card networks, which notifies issuing banks, which in turn notifies consumers.

The Denver-based chain said earlier that sales rose 17.8 percent at established locations for the three months ended March 31, following a 29.7 percent decline in the year-ago quarter. Sales at stores open at least 13 months had turned positive in December after dropping steeply starting in late 2015. The 13-month metric is a considered a key indicator because it strips out the volatility of newly opened and closed locations.

Its 52-week range quite noticeable, lower range was $33.66% and hit highest level of $-2.43%. The overall volume in the last trading session was 1.62 Million shares. The firm shares 50 day moving average was calculated 9.66%. How Inside Factors Effect NYSE:CMG? Find Out Here Totally Free

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) closed at $1.48 by decreasing -1.33% in last trading session with share volume of 14.33 Million that was surprisingly higher than its average volume of 1958.78 shares. Catabasis Pharmaceuticals (CATB) reported that additional favorable results across multiple functional assessments in the MoveDMD trial at the American Academy of Neurology Meeting. The firm reported additional favorable results across multiple functional assessments in the MoveDMD trial at the American Academy of Neurology 69th Annual Meeting.

In Part B of the MoveDMD trial, designed to evaluate the potential of edasalonexent in the treatment of Duchenne muscular dystrophy (DMD), numerical improvements were seen in prespecified rate change analyses across five functional assessments. These results are in addition to and consistent with the numerical improvements in the same functional assessments with edasalonexent compared to placebo after 12 weeks of edasalonexent treatment.

“Following our completed analysis of the rate of change data from Part B of the MoveDMD trial, we are encouraged by the consistency of the possible treatment effects across the range of functional assessments after only 12 weeks of dosing as well as the numerical improvements in functional assessments compared to placebo. These functional assessments are meaningful to boys affected by Duchenne and are known to correlate with loss of milestones and disease progression,” said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis. “Coupled with the reassuring safety, tolerability and plasma exposure data in patients affected by Duchenne, we are optimistic about edasalonexent’s potential and look forward to continuing to evaluate it as a novel treatment for this devastating disease.”

The share is moved forward to its percent change from 52-week low of 37.04% and hanging back from its percent change from 52-week high of -81.24%. Hot And Soar Facts About NASDAQ:CATB, Find Out Here